Glycomimetics (GLYC) Finds a New Pathway to Approval - Roth Capital
Tweet Send to a Friend
Roth Capital analyst Zegbeh Jallah reiterated a Buy rating and $9.00 price target on Glycomimetics (NASDAQ: GLYC) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
